273 related articles for article (PubMed ID: 19584240)
1. D,L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells.
Kim SH; Singh SV
Mol Cancer Ther; 2009 Jul; 8(7):1946-54. PubMed ID: 19584240
[TBL] [Abstract][Full Text] [Related]
2. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
Khurana N; Talwar S; Chandra PK; Sharma P; Abdel-Mageed AB; Mondal D; Sikka SC
Int J Oncol; 2016 Oct; 49(4):1609-19. PubMed ID: 27499349
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional repression and inhibition of nuclear translocation of androgen receptor by diallyl trisulfide in human prostate cancer cells.
Stan SD; Singh SV
Clin Cancer Res; 2009 Aug; 15(15):4895-903. PubMed ID: 19622577
[TBL] [Abstract][Full Text] [Related]
4. Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate.
Wang LG; Liu XM; Chiao JW
Carcinogenesis; 2006 Oct; 27(10):2124-32. PubMed ID: 16704988
[TBL] [Abstract][Full Text] [Related]
5. D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1.
Choi S; Lew KL; Xiao H; Herman-Antosiewicz A; Xiao D; Brown CK; Singh SV
Carcinogenesis; 2007 Jan; 28(1):151-62. PubMed ID: 16920735
[TBL] [Abstract][Full Text] [Related]
6. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
7. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Bhattacharyya RS; Krishnan AV; Swami S; Feldman D
Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513
[TBL] [Abstract][Full Text] [Related]
8. Notch activation is dispensable for D, L-sulforaphane-mediated inhibition of human prostate cancer cell migration.
Hahm ER; Chandra-Kuntal K; Desai D; Amin S; Singh SV
PLoS One; 2012; 7(9):e44957. PubMed ID: 22970326
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
[TBL] [Abstract][Full Text] [Related]
10. Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells.
Chiao JW; Chung FL; Kancherla R; Ahmed T; Mittelman A; Conaway CC
Int J Oncol; 2002 Mar; 20(3):631-6. PubMed ID: 11836580
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
12. Sulforaphane inhibits constitutive and interleukin-6-induced activation of signal transducer and activator of transcription 3 in prostate cancer cells.
Hahm ER; Singh SV
Cancer Prev Res (Phila); 2010 Apr; 3(4):484-94. PubMed ID: 20233902
[TBL] [Abstract][Full Text] [Related]
13. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
14. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.
Dai Y; Ngo D; Jacob J; Forman LW; Faller DV
Carcinogenesis; 2008 Sep; 29(9):1725-33. PubMed ID: 18487222
[TBL] [Abstract][Full Text] [Related]
15. Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LNCaP human prostate cancer cell line.
Herman-Antosiewicz A; Xiao H; Lew KL; Singh SV
Mol Cancer Ther; 2007 May; 6(5):1673-81. PubMed ID: 17513615
[TBL] [Abstract][Full Text] [Related]
16. Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells.
Hsu JC; Zhang J; Dev A; Wing A; Bjeldanes LF; Firestone GL
Carcinogenesis; 2005 Nov; 26(11):1896-904. PubMed ID: 15958518
[TBL] [Abstract][Full Text] [Related]
17. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
Gan L; Chen S; Wang Y; Watahiki A; Bohrer L; Sun Z; Wang Y; Huang H
Cancer Res; 2009 Nov; 69(21):8386-94. PubMed ID: 19826044
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
[TBL] [Abstract][Full Text] [Related]
20. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
Siddique HR; Mishra SK; Karnes RJ; Saleem M
Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
